Zenitar Biotech_Providing professional financial news and data related to Zenitar Biotech, committed to creating a comprehensive and efficient information access channel for users | NewTimeSpace

Zenitar Biotech：Hong Kong IPO Application Lapsed, Core Assets Flonoltinib Maleate and Purinostat Mesylate Under Phase III Registrational Clinical Trials

Tags：

Zenitar Biotech IPO IPO application lapsed

2026-07-13

NewTimeSpace丨Nearly RMB 1.2 Billion Raised Over 5 Years, Revenue-less Zenitar Biotech Files for Hong Kong IPO

Tags：

Zenitar Biotech IPO NewTimeSpace Research

2026-01-20

ETF
Semiconductor memory stocks rebound across the board; E Fund (Hk) Solactive Asia Semiconductor Select Index Etf (03486) gains over 6%
ETF
Samsung Global Semi(03132.HK) up 2.99%, Supermicro's results beat market expectations
Research
HK Stock Connect Insight | HQVT (01392.HK) First-Half Revenue Up 84.5% YoY, Down 23.78% Since Stock Connect Inclusion
Finance
SBP GROUP (01177.HK): TQC2731 Phase III fully enrolled in CRSwNP
Finance
HUTCHMED (00013.HK): GSK licence deal for KRAS-EGFR ATTC closes
Finance
GF SEC (01776.HK): tech innovation bond coupon set at 1.60%
Finance
JSMART TECH (00567.HK): grants 161,328,757 share options at HK$ 0.28
Finance
BRETON (01333.HK): president Qiu Debo resigns; Yang Hui appointed
Finance
VOBILE GROUP (03738.HK): completes Anqing International acquisition
Finance
SEVEN ELEMENTS (01660.HK): completes Tung Wui Securities deal

Scan QR Code

Download App